Skip to main content

Australia

Alexion Mission

At Alexion, our mission is to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, as well as supportive technologies and healthcare services.

For over three decades, patients and their caregivers have been at the centre of everything we do. Everyday, we are inspired to think differently and follow the science in order to create better outcomes for them and their families. Our mission is driven by understanding who they are as unique individuals, not just their disease.

Alexion in Australia

Alexion established operations in Sydney in 2008 to serve patients in the Australian region. We aim to work in partnership with stakeholders including healthcare providers, patient advocacy organisations, and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we aim to help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.

Medicines

Our Medicines:

SOLIRIS®

(eculizumab rmc)

Is registered in Australia for the treatment of atypical haemolytic uraemic syndrome (aHUS) and paroxysmal nocturnal haemoglobinuria (PNH) to reduce haemolysis, and for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. SOLIRIS is listed on the Pharmaceutical Benefits Scheme (PBS) as a Section 100 item for aHUS and PNH. For the treatment of NMOSD, SOLIRIS is not reimbursed on the PBS.

ULTOMIRIS®

(ravulizumab rch)

Is registered in Australia for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS), as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetycholine receptor (AChR) antibody-positive and for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ULTOMIRIS is listed on the PBS as a Section 100 item for the treatment of aHUS and PNH. Ultomiris is not listed on the PBS for the treatment of adult patients with gMG who are AChR antibody-positive or for adult patients with NMOSD who are AQP4 antibody positive.

VOYDEYA®

(danicopan)

Is registered in Australia as an add-on to ravulizumab or eculizumab for the treatment of the signs or symptoms of extravascular haemolysis (EVH) in adult patients with paroxysmal nocturnal haemoglobinuria (PNH). VOYDEYA is not reimbursed on the PBS.

KANUMA®

(sebelipase alfa rce)

Is registered in Australia for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-D). LAL-D is a progressive and ultra-rare metabolic disease. KANUMA® is funded under the Life Saving Drugs Program for infantile-onset LAL-D.

KOSELUGO®

(selumetinib)

Is registered in Australia for the treatment of paediatric patients aged 2 years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). KOSELUGO is listed on the PBS as a Section 85 item for the treatment of paediatric patients aged 2 to 18 years, with NF1 who have symptomatic, inoperable PN.

Soliris, Ultomiris, Voydeya and Koselugo are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

Patient Advocacy

We seek to understand and incorporate insights from people living with rare diseases and their caregivers into our development plans, medicines, and services. Our promise is to partner with the rare disease community to understand the patient experience as the community searches for diagnosis, treatment, disease education, and condition management. We work closely with patient advocacy groups to realise shared ambitions whilst respecting the privacy and independence of all parties.

We are industry members of Rare Voices Australia and Rare Disorders New Zealand. We follow the Medicines Australia Working Together Guide in our collaborations with patient advocacy groups.

Clinical Trials

Clinical Trials

Alexion is committed to serving people affected by rare diseases through the discovery, development and access of life-changing medicines. Our goal is to bring effective medicines to as many patients as possible by conducting rigorous clinical trials and obtaining marketing approval by regulatory authorities around the world. Our work is marked by a commitment to the highest standards of preclinical and clinical research, and an acute sense of urgency. As such, we prioritise access to our investigational medicines through participation in a clinical trial.

To find out more about a clinical trial, please speak with your healthcare provider, or search for clinical trials in Australia

Clinical trials in Australia Contact us
Careers

Career Opportunities

At Alexion, we foster an environment that attracts and retains the best talent. We provide the tools to enable each individual to perform at their personal best so that we maximize our collective impact.

Explore Careers

Contact Information

Adverse Events

 

Product Quality Complaints

T: 1800 625 245

Medical Information

T: 1800 788 189 

Australia Office

Alexion Pharmaceuticals Australasia Pty Ltd

66 Talavera Rd,
Macquarie Park
NSW 2113

F: +61 (2) 9091 0511

T: +61 (2) 9091 0500

Leaving Our Site

You are now going to another site.